Literature DB >> 15716284

The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina.

Caroline A Daly1, Felicity Clemens, Jose L Lopez Sendon, Luigi Tavazzi, Eric Boersma, Nicholas Danchin, Francois Delahaye, Anselm Gitt, Desmond Julian, David Mulcahy, Witold Ruzyllo, Kristian Thygesen, Freek Verheugt, Kim M Fox.   

Abstract

AIMS: In order to assess adherence to guidelines and international variability in management, the Euro Heart Survey of Newly Presenting Angina prospectively studied medical therapy, percutaneous coronary intervention (PCI), and surgery in patients with new-onset stable angina in Europe. METHODS AND
RESULTS: Consecutive patients, 3779 in total, with a clinical diagnosis of stable angina by a cardiologist were enrolled. After initial assessment by a cardiologist, 78% were treated with aspirin, 48% with a statin, and 67% with a beta-blocker. ACE-inhibitors were prescribed by the cardiologist in 37% overall. Revascularization rates were low, with only 501 (13%) patients having PCI or coronary bypass surgery performed or planned. However, when restricted to patients with coronary disease documented within 4 weeks of assessment, over 50% had revascularization performed or planned. Among other factors, the national rate of angiography and availability of invasive facilities significantly predicted the likelihood of revascularization, OR 2.4 and 2.0, respectively.
CONCLUSION: This survey shows a shortfall between guidelines and practice with regard to the use of evidence-based drug therapy and evidence that revascularization rates are strongly influenced by non-clinical, in addition to clinical, factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716284     DOI: 10.1093/eurheartj/ehi109

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

1.  Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study.

Authors:  N F Murphy; C R Simpson; K MacIntyre; F A McAlister; J Chalmers; J J V McMurray
Journal:  Heart       Date:  2006-01-06       Impact factor: 5.994

2.  Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany.

Authors:  B Bischoff; Sigmund Silber; B M Richartz; L Pieper; J Klotsche; H-U Wittchen
Journal:  Clin Res Cardiol       Date:  2006-07-03       Impact factor: 5.460

3.  Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.

Authors:  Alvaro Hidalgo-Vega; Juan Manuel Ramos-Goñi; Renata Villoro
Journal:  Eur J Health Econ       Date:  2014-12

Review 4.  Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution.

Authors:  Adam D Timmis; Gene Feder; Harry Hemingway
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

Review 5.  Perspectives of I(f) inhibition by ivabradine in cardiology.

Authors:  Michael Böhm; Jan-Christian Reil
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Treatment of chronic CAD--do the guidelines (ESC, AHA) reflect daily practice?

Authors:  Harald Tillmanns; Ali Erdogan; Daniel Sedding
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

Review 7.  Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease.

Authors:  Harry Hemingway; Peter Philipson; Ruoling Chen; Natalie K Fitzpatrick; Jacqueline Damant; Martin Shipley; Keith R Abrams; Santiago Moreno; Kate S L McAllister; Stephen Palmer; Juan Carlos Kaski; Adam D Timmis; Aroon D Hingorani
Journal:  PLoS Med       Date:  2010-06-01       Impact factor: 11.069

8.  Angina: Ivabradine for treatment of stable angina pectoris.

Authors:  Ranil de Silva; Kim M Fox
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

9.  Profiles of Hospitalized Patients with Angiographic Coronary Heart Disease in Taiwan during 2014-2016: Report of a Tertiary Hospital.

Authors:  Wen-Yu Lin; Yuan Hung; Gen-Min Lin; Chin-Sheng Lin; Jun-Ting Liou; Cheng-Chung Cheng; Tsung-Neng Tsai; Wei-Che Tsai; Tzu-Chiao Lin; Wen-Cheng Liu; Pang-Yen Liu; Keng-Yi Wu; Chih-Hsueng Hsu; Fang-Han Yu; Shu-Meng Cheng; Shih-Ping Yang; Wei-Shiang Lin; Chun-Hsien Wu
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

10.  Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.

Authors:  Jean-Claude Tardif; Piotr Ponikowski; Thomas Kahan
Journal:  Eur Heart J       Date:  2009-01-09       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.